-
Key Brands
-
Revenue
-
Performance
| Emla | Maltofer | Magnesia Bisurada |
Mybulen | Ovestin | Solpadeine | Xylocaine Topicals |
|---|---|---|---|---|---|---|
| Topical anaesthetic |
Iron supplement |
Antacid | Analgesic anti- inflammatory |
Hormone replacement therapy |
Opioid analgesic |
Topical analgesic |
2025
22%
of Group revenue
30%
of Group gross profit
Africa Middle East
38
Australasia
25
Europe CIS
20
Americas
14
Asia
3
| Revenue | 2025 R'million |
2024 R'million |
% Change Reported |
CER |
|---|---|---|---|---|
| Africa Middle East | 3 746 | 3 561 | 5 | 6 |
| Australasia | 2 448 | 2 430 | 1 | 5 |
| Europe CIS | 1 973 | 1 974 | 0 | 2 |
| Americas | 1 329 | 1 450 | (8) | 4 |
| Asia | 316 | 291 | 9 | 12 |
| Total | 9 812 | 9 706 | 1 | 5 |
| Gross profit (%) | 58.3 | 58.7 |
The OTC segment reported good organic growth across all regions. For FY2025, revenue increased by 1%
(5% CER) to R9 812 million, buoyed by an expected stronger second half performance from Africa Middle East,
which recorded full year growth of 5% (6% CER). Australasia, the second largest OTC region, grew by 1%
(5% CER) and the portfolio now exceeds the region’s Prescription segment and is well positioned for future
revenue growth. Europe CIS enjoyed a 2% CER growth supported by a key hormonal cream brand, Ovestin.
Gross profit percentage of 58,3% was closely aligned with the prior period (FY2024: 58,7%).
Gross profit percentage of 58,3% was closely aligned with the prior period (FY2024: 58,7%).
